Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors

Xu, Xiaoqing; Chlebowski, Rowan T.; Shi, Jiaxiao; Barac, Ana; Haque, Reina

doi:10.1007/s10549-018-05086-8

Cited by 53 publications

(53 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7 Compared with AI use, VTE risk with tamoxifen was at least 40% higher. 48 Specific to tamoxifen is also an increased risk of endometrial cancer, seen in 5.5 per 1000 women. 7 For AI use, a significant risk is related to the increased bone resorption leading to osteopenia and fractures.…”

Section: Map3 and Ibis-ii Performed Subgroup Analysis Of Women Withmentioning

confidence: 99%

Management of women at increased risk for breast cancer secondary to high‐risk proliferative lesions and family history of the disease

2020

View full text Add to dashboard Cite

Women with breast biopsies showing high‐risk proliferative lesions such as atypical hyperplasia (AH) and lobular carcinoma in situ (LCIS) have an increased risk of developing breast cancer. Other factors including age, family history of breast cancer, and extent of AH may play a role in increasing breast cancer risk. In addition to women with AH, there is a subset of women with a positive family history of breast cancer, without a known germline mutation, which places them also at an increased risk for breast cancer. Clinical management, screening, chemoprevention, and surgical risk‐reduction are discussed in this review to inform the management of these high‐risk women. Advanced imaging technology, pharmacologic research into different targets, and innovations in breast reconstruction are changing the way in which patients are counseled of their individual risk.

show abstract

Section: Map3 and Ibis-ii Performed Subgroup Analysis Of Women Withmentioning

confidence: 99%

Management of women at increased risk for breast cancer secondary to high‐risk proliferative lesions and family history of the disease

2020

View full text Add to dashboard Cite

show abstract

“…GnRHa resulted in a higher risk of thromboembolic disease than the comparison cohort in men with prostate cancer 30,31 . Breast cancer patients are at an increased risk of VTE, and tamoxifen therapy is reported to increase that risk 11,32–35 . A Danish population‐based cohort study showed that women treated with tamoxifen were at a higher risk of VTE during the first 2 years after exposure, especially older women 32 .…”

Section: Discussionmentioning

confidence: 99%

“…30,31 Breast cancer patients are at an increased risk of VTE, and tamoxifen therapy is reported to increase that risk. 11,[32][33][34][35] A Danish population-based cohort study showed that women treated with tamoxifen were at a higher risk of VTE during the first 2 years after exposure, especially older women. 32 A systematic review of long-term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors suggested an increased risk of VTE in tamoxifen users compared with both non-users and aromatase inhibitor users, and a higher risk of MI and angina in aromatase inhibitor users compared with tamoxifen users.…”

Section: Thromboembolism and Purpose Of Female Hormone Usementioning

confidence: 99%

“…11 Another study revealed that aromatase inhibitor use was associated with at least a 41% lower risk of VTE than tamoxifen use. 33 On the other hand, a retrospective cohort of postmenopausal women with breast cancer showed that aromatase inhibitor-only users had a risk of MI or angina and stroke similar to tamoxifen-only users. 34 VTE and stroke are risks of all estrogen-based therapies, including SERM.…”

Section: Thromboembolism and Purpose Of Female Hormone Usementioning

confidence: 99%

See 1 more Smart Citation

National survey of confirmed thromboembolism related to female hormones in Japan

Sugiura

Kobayashi

Ojima

2020

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Aim: The aim of this study was to determine the number of thromboembolism patients among Japanese users of female hormones. Methods: A survey of confirmed thromboembolism patients among Japanese users of female hormones was conducted at randomly selected hospitals from across Japan. The survey examined six types of venous thromboembolism (VTE) and arterial thromboembolism (ATE) in all users of female hormones, including women and men: pulmonary embolism (PE), deep vein thrombosis (DVT), other venous thrombosis (other VTE), cerebral infarction (stroke), myocardial infarction (MI) and other arterial thrombosis (other ATE). The survey covered 5 years from 2009 to 2013. This study was approved in an ethical review by the Hamamatsu University School of Medicine. Results: The overall number of thromboembolism patients over the 5 years was estimated to be about 3211. They included 452 patients with PE, 795 with DVT, 157 with other VTE, 1228 with stroke, 478 with MI and 101 with other ATE. Among the abovementioned conditions, detailed information was available for 750 thromboembolism patients (645 women and 105 men), including 63 PE, 203 DVT, 159 PE + DVT, 65 other VTE, 189 stroke, 35 MI, 21 other ATE and 15 other cases. Thromboembolism increased year by year. The number of VTE was larger than that of ATE in younger people who used female hormones, while the number of ATE was larger than that of VTE in older people who used female hormones. Conclusion:The number and characteristics of thromboembolism patients among Japanese female hormone users were revealed in this national survey.

show abstract

“…Several reports suggest that AIs present a more favorable risk-benefit profile, compared to Tamoxifen, with a lower incidence of life-threatening adverse events, including thromboembolic episodes and occurrence of endometrial cancer, other than a better antitumor efficacy [7].…”

Section: Introductionmentioning

confidence: 99%

Aromatase Inhibitors—Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects

Tenti

Correale

Cheleschi

et al. 2020

IJMS

View full text Add to dashboard Cite

Aromatase inhibitors (AIs) have radically changed the prognosis of hormone receptor positive breast cancer (BC) in post-menopausal women, and are a mainstay of the adjuvant therapy for BC after surgery in place of, or following, Tamoxifen. However, AIs aren’t side effect-free; frequent adverse events involve the musculoskeletal system, in the form of bone loss, AI-associated arthralgia (AIA) syndrome and autoimmune rheumatic diseases. In this narrative review, we reported the main clinical features of these three detrimental conditions, their influence on therapy adherence, the possible underlying molecular mechanisms and the available pharmacological and non-pharmacological treatments. The best-known form is the AIs-induced osteoporosis, whose molecular pathway and therapeutic possibilities were extensively investigated in the last decade. AIA syndrome is a high prevalent joint pain disorder which often determines a premature discontinuation of the therapy. Several points still need to be clarified, as a universally accepted diagnostic definition, the pathogenetic mechanisms and satisfactory management strategies. The association of AIs therapy with autoimmune diseases is of the utmost interest. The related literature has been recently expanded, but many issues remain to be explored, the first being the molecular mechanisms.

show abstract

Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors

Cited by 53 publications

References 26 publications

Management of women at increased risk for breast cancer secondary to high‐risk proliferative lesions and family history of the disease

Management of women at increased risk for breast cancer secondary to high‐risk proliferative lesions and family history of the disease

National survey of confirmed thromboembolism related to female hormones in Japan

Aromatase Inhibitors—Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects

Contact Info

Product

Resources

About